Article · 28 Aug 2024
Conference abstractPublished 28 Sep 2018
Understanding Q hypotheses for developing topical generic drugs
TOLMAR Inc, USA
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Topical drug delivery is considered one of the safest and easiest drug delivery approaches for many reasons. Topical formulations are designed to deliver drugs to the skin to treat skin disease conditions or to alleviate symptoms. Developing a dermatology generic drug product involves many regulations and needs the critical understanding of the test product as well as reference product in order to make the test formulation structurally and functionally similar to the reference product. Current regulations require conducting clinical endpoint trials for demonstrating bioequivalence (BE) between topical generic and reference listed drug (RLD) products. A variety of surrogate methods have been explored but with limited success. FDA has been continuously coming up with new regulatory standards to make high quality and affordable medicines available to public and the generic industry is trying to adapt to the new requirements. Bioequivalence studies on topical products still remained one of the challenging topics in the generic industry because of two reasons: i) due to high complexity of topical dosage forms ii) due to lack of proper design of BE studies. The new GDUFA II guidance gives a clear pathway to assist generic pharmaceutical industry with identifying the most relevant methodologies for developing drugs and generating evidence needed to support ANDA approval. To develop a therapeutically equivalent drug product to a specific reference product, it is necessary to identify the key scientific principles for consistent and efficient identification of BE methods. Availability of product quality matrices i.e. Q1 (qualitatively the same), Q2 (quantitatively the same) and Q3 (microstructure/ physical attributes of the topical dosage form) is critical to demonstrate that generic topical product is therapeutically equivalent.
Subjects
DermatologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Short communication · 31 Oct 2023
Understanding Generic Drugs and Their Impact on Healthcare
Conference abstract
Development of a generic tissue engineering research platform for the mechanistic understanding of tissue regeneration
Conference abstract · 13 Aug 2018
A single treatment of melasma using drug delivery with CO2 fractional laser and a topical cream containing hydroquinone 4%, tretinoin 0.05%, fluocinolone acetonide 0.01%
Conference abstract · 14 Jul 2016
Assessing the bioavailability and bioequivalence of topical dermatologic drug products with multiple surrogate tests
More from this journal
The newest in Journal of Clinical & Experimental Dermatology Research.
Research article · 30 Jul 2026
MINIMALLY-INVASIVE LASER-ASSISTED (MILA) FACELIFT UNDER LOCAL ANESTHESIA
Commentary · 30 Jul 2026
Breaking the Stigma Around Psoriasis: A Broader View of Chronic Skin Disease
Perspective · 28 Jul 2026
Acne as More Than a Cosmetic Concern: A Personal and Medical Perspective
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Clinical & Experimental Dermatology Research
- SubjectDermatology
- BylineArticles whose byline prints “Hima Bindu Gottam”

